Evaluation of the healthy liver using new magnetic resonance imaging and spectroscopy methods at 3.0T and 7.0T

Evaluation of the healthy liver using new magnetic resonance imaging and spectroscopy methods at 3.0T and 7.0T - 31P-MRS @ 3.0T and 7.0T

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36052

Enrollment

Registered

2011-07-29

Start date

2012-06-06

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers, 18 years or older Written informed consent

Exclusion criteria

Exclusion criteria: - Healthy volunteers under 18 years of age - Alcohol consumption of >3 units/day for males and >2 units/day for females (steatogenic effect) - Contraindications for MRI (with the use of standard MRI checklist, see document E4) - Body Mass Index (BMI) >27 (there is a high prevalence of hepatic steatosis in overweight persons) - Diabetes Mellitus - History of or current treatment for liver disease - Use of medications known to have steatogenic effects on the liver: synthetic estrogens, corticosteroids, diltiazem, nifedipine, perhexilline, amiodarone, metformine, insulin, statins, rosiglitazon, methotrexate, antiretroviral therapy, tamoxifen, tetracycline, valproate

Design outcomes

Primary

Measure	Time frame
For 31P-MRS: Liver phosphorus metabolite ratios For DTI-MRI: Apparent Diffusion Coefficient (ADC)-values of the liver; Fractional Anisotropy (FA)-values of the liver	—

Secondary

Measure	Time frame
For 31P-MRS: Spectral resolution (line width); Signal to Noise Ratio (SNR); T1 measurements For 1H-MRS: Liver fat percentage; Identification of individual fat peaks	—

Countries

Netherlands

Outcome results